CL2018000103A1 - Anticuerpo anti-cd154 con características de unión, funcionalidad y seguridad mejoradas y uso en inmunoterapia humana - Google Patents

Anticuerpo anti-cd154 con características de unión, funcionalidad y seguridad mejoradas y uso en inmunoterapia humana

Info

Publication number
CL2018000103A1
CL2018000103A1 CL2018000103A CL2018000103A CL2018000103A1 CL 2018000103 A1 CL2018000103 A1 CL 2018000103A1 CL 2018000103 A CL2018000103 A CL 2018000103A CL 2018000103 A CL2018000103 A CL 2018000103A CL 2018000103 A1 CL2018000103 A1 CL 2018000103A1
Authority
CL
Chile
Prior art keywords
antibody
functionality
safety
binding characteristics
improved binding
Prior art date
Application number
CL2018000103A
Other languages
English (en)
Spanish (es)
Inventor
Jay Rothstein
Robert George Edward Holgate
Arron Hearn
Original Assignee
Immunext Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunext Inc filed Critical Immunext Inc
Publication of CL2018000103A1 publication Critical patent/CL2018000103A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
CL2018000103A 2015-07-14 2018-01-12 Anticuerpo anti-cd154 con características de unión, funcionalidad y seguridad mejoradas y uso en inmunoterapia humana CL2018000103A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562192269P 2015-07-14 2015-07-14
US201562197966P 2015-07-28 2015-07-28
US201662277201P 2016-01-11 2016-01-11

Publications (1)

Publication Number Publication Date
CL2018000103A1 true CL2018000103A1 (es) 2018-06-29

Family

ID=57757587

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018000103A CL2018000103A1 (es) 2015-07-14 2018-01-12 Anticuerpo anti-cd154 con características de unión, funcionalidad y seguridad mejoradas y uso en inmunoterapia humana

Country Status (27)

Country Link
US (3) US10874738B2 (enExample)
EP (2) EP3331548B8 (enExample)
JP (4) JP6826113B2 (enExample)
KR (2) KR20250099272A (enExample)
CN (2) CN114671952A (enExample)
AU (3) AU2016294417B2 (enExample)
CL (1) CL2018000103A1 (enExample)
CO (1) CO2018001363A2 (enExample)
CR (1) CR20180097A (enExample)
DK (1) DK3331548T3 (enExample)
DO (1) DOP2018000018A (enExample)
EA (1) EA201890297A1 (enExample)
EC (1) ECSP18009949A (enExample)
ES (1) ES3075638T3 (enExample)
FI (1) FI3331548T3 (enExample)
GT (1) GT201800018A (enExample)
IL (3) IL310460A (enExample)
LT (1) LT3331548T (enExample)
MX (2) MX2018000548A (enExample)
MY (2) MY203911A (enExample)
PE (1) PE20180741A1 (enExample)
PH (1) PH12018500098A1 (enExample)
PT (1) PT3331548T (enExample)
RS (1) RS68307B1 (enExample)
SG (1) SG10201913431QA (enExample)
TN (1) TN2018000021A1 (enExample)
WO (1) WO2017011544A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11248055B2 (en) 2015-11-27 2022-02-15 Ablynx N.V. Polypeptides inhibiting CD40L

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913431QA (en) * 2015-07-14 2020-03-30 Immunext Inc Anti-cd154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy
WO2019195770A1 (en) 2018-04-06 2019-10-10 Atyr Pharma, Inc. Compositions and methods comprising anti-nrp2 antibodies
WO2020056162A1 (en) * 2018-09-12 2020-03-19 Oregon Health & Science University Detecting and/or subtyping circulating hybrid cells that correlate with stage and survival
WO2020068723A1 (en) * 2018-09-24 2020-04-02 Janssen Biotech, Inc. Method of providing safe administration of an anti-cd154 antibody
CN115227824A (zh) * 2018-11-12 2022-10-25 中南大学湘雅二医院 免疫检查点的抑制剂在制备治疗青光眼和其他眼部免疫损伤机制相关疾病药物中的应用
CA3136725A1 (en) * 2019-04-12 2020-10-15 Tonix Pharmaceuticals Holding Corp. Inhibitors of cd40-cd154 binding
AU2020358854B2 (en) * 2019-10-03 2026-08-13 Atyr Pharma, Inc. Compositions and methods comprising anti-NRP2 antibodies
CN113488170B (zh) * 2021-07-02 2023-07-25 温州医科大学 急性前葡萄膜炎复发风险预测模型构建方法及相关设备
WO2023008982A1 (ko) * 2021-07-30 2023-02-02 서울대학교산학협력단 항 cd154 항체 및 이의 용도
EP4382537A4 (en) * 2021-07-30 2025-07-23 Seoul Nat Univ R&Db Foundation ANTI-CD154 ANTIBODY AND ITS USE
WO2024211211A1 (en) 2023-04-03 2024-10-10 Regeneron Pharmaceuticals, Inc. Methods of improving transplant survival using il-2 receptor gamma chain antibodies
EP4703385A1 (en) * 2023-04-28 2026-03-04 Fortvita Biologics Inc. Anti-cd40l antibody and use thereof in treatment of human autoimmune diseases
US20240392022A1 (en) 2023-05-22 2024-11-28 Genzyme Corporation Treatment of multiple sclerosis with anti-cd40l antibodies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1127351C (zh) 1993-09-02 2003-11-12 达特茅斯学院理事 诱导抗原特异性ｔ细胞耐受的方法
US6440418B1 (en) * 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6444018B1 (en) 1998-06-25 2002-09-03 Xerox Corporation Phase change ink carrier compositions containing anhydride/amino alcohol-based adducts
GB0006398D0 (en) * 2000-03-16 2000-05-03 Novartis Ag Organic compounds
NZ525793A (en) 2000-10-13 2008-04-30 Biogen Idec Inc Humanized anti-LT-beta-R antibodies
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
DK1639014T3 (da) 2003-06-13 2011-01-17 Biogen Idec Inc Aglycosyl-anti-CD154 (CD40-ligand)-antistoffer og anvendelser deraf
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
US20110123440A1 (en) 2005-03-29 2011-05-26 Genevieve Hansen Altered Antibody FC Regions and Uses Thereof
BRPI0809042B1 (pt) * 2007-03-22 2021-08-31 Biogen Ma Inc. Proteína de ligação a cd154 isolada, seu uso, e composição
US9321833B2 (en) * 2011-04-04 2016-04-26 The Trustees Of Dartmouth College Methods of therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties
WO2012138768A2 (en) * 2011-04-04 2012-10-11 Trustees Of Dartmouth College Anti-cd154 antibodies having impaired fcr binding and/or complement binding properties and the use thereof in immune therapies
SG10201913431QA (en) * 2015-07-14 2020-03-30 Immunext Inc Anti-cd154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11248055B2 (en) 2015-11-27 2022-02-15 Ablynx N.V. Polypeptides inhibiting CD40L

Also Published As

Publication number Publication date
KR20250099272A (ko) 2025-07-01
AU2022263520B2 (en) 2025-06-05
IL297907A (en) 2023-01-01
IL310460A (en) 2024-03-01
WO2017011544A1 (en) 2017-01-19
CA2992116A1 (en) 2017-01-19
EP4732909A2 (en) 2026-04-29
CR20180097A (es) 2018-05-25
CN114671952A (zh) 2022-06-28
PH12018500098A1 (en) 2018-07-09
IL256800B (en) 2022-12-01
AU2022263520A1 (en) 2022-12-08
KR102825142B1 (ko) 2025-06-26
AU2016294417A1 (en) 2018-03-08
EP3331548A1 (en) 2018-06-13
MY203911A (en) 2024-07-24
HK1249735A1 (en) 2018-11-09
EP3331548B1 (en) 2026-04-15
AU2025226796A1 (en) 2025-09-25
TN2018000021A1 (en) 2019-07-08
CN108135969A (zh) 2018-06-08
JP6826113B2 (ja) 2021-02-03
MX2023014921A (es) 2024-02-16
MY196991A (en) 2023-05-17
NZ739859A (en) 2024-08-30
IL297907B1 (en) 2024-03-01
PE20180741A1 (es) 2018-04-27
DOP2018000018A (es) 2019-10-15
RS68307B1 (en) 2026-07-31
US20240000929A1 (en) 2024-01-04
FI3331548T3 (fi) 2026-08-05
CO2018001363A2 (es) 2018-05-10
US11596689B2 (en) 2023-03-07
US12653884B2 (en) 2026-06-16
EA201890297A1 (ru) 2018-06-29
CN108135969B (zh) 2022-03-04
US20210145966A1 (en) 2021-05-20
US10874738B2 (en) 2020-12-29
GT201800018A (es) 2019-08-08
PT3331548T (pt) 2026-07-17
IL297907B2 (en) 2024-07-01
DK3331548T3 (da) 2026-06-29
MX2018000548A (es) 2018-09-26
JP7605914B2 (ja) 2024-12-24
SG10201913431QA (en) 2020-03-30
KR20180037984A (ko) 2018-04-13
EP4732909A3 (en) 2026-07-29
IL256800B2 (en) 2023-04-01
JP2021063129A (ja) 2021-04-22
IL256800A (en) 2018-03-29
AU2016294417B2 (en) 2022-08-04
US20180193454A1 (en) 2018-07-12
JP2018528258A (ja) 2018-09-27
EP3331548A4 (en) 2019-02-13
BR112018000653A2 (pt) 2018-09-18
JP2023123812A (ja) 2023-09-05
ECSP18009949A (es) 2018-10-31
JP2025038055A (ja) 2025-03-18
EP3331548B8 (en) 2026-08-05
ES3075638T3 (en) 2026-08-06
LT3331548T (lt) 2026-07-27

Similar Documents

Publication Publication Date Title
GT201800018A (es) Anticuerpo anti-cd154 con características de unión, funcionalidad y seguridad mejoradas y uso en inmunoterapia humana
SV2018005659A (es) Anticuerpos agonistas que se unen especificamente a cd40 humanos y metodos de uso
MX2024011328A (es) Proteinas de union gfral y uso de las mismas
CU24437B1 (es) Anticuerpos agonistas de anti-gitr y composiciones de los mismos
MX2022014761A (es) Anticuerpos biespecificos contra beta amiloide humana/receptor de transferrina humano y metodos de uso.
MX375032B (es) Proteínas de unión y métodos para utilizarlas.
CL2017003023A1 (es) Anticuerpos anti-ctla-4 y métodos de uso de los mismos.
ECSP18096095A (es) Anticuerpos a la alfa-sinucleína y usos de los mismos
CO2018006297A2 (es) Composiciones y métodos para disminuir la expresión de tau
CL2017000201A1 (es) Composiciones y métodos de uso para tratar trastornos metabólicos
MX2015010836A (es) Tratamiento de cancer utilizando un receptor quimerico de antigeno anti egfrviii humanizado.
PE20151925A1 (es) Anticuerpos anti-igf-1r con abolicion de la union al fcrn y su utilizacion en el tratamiento de enfermedades oculares vasculares
MX2017005344A (es) Composiciones y metodos para reforzar la eficacia de inmunoterapia celular adoptiva.
UY36021A (es) Proteìnas fc multimèricas
MX2015009104A (es) Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares.
UA123202C2 (uk) Антитіло до тау-білка і його застосування
CL2018001427A1 (es) Composiciones de anticuerpo injertado con citoquina y métodos para su uso en inmunorregulación.
CL2017001135A1 (es) Anticuerpos mejorados contra il-6
MX2018005825A (es) Celulas inmunes modificadas y usos de las mismas.
CL2017000212A1 (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso
AR095334A1 (es) Composiciones nutricionales que contienen un componente peptídico con propiedades estimulantes de la adiponectina y método para promover un peso corporal saludable
AR101671A1 (es) Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso
CR20160369A (es) Composiciones para uso en el tratamiento de afecciones alérgicas
AR102495A1 (es) Anticuerpos contra el dominio 3 de la inmunoglobulina y de la mucina del linfocito t (tim3) y métodos de uso
TH1501004430A (th) แอนทิบอดีแอนทิ-il-17a และการใช้ของสิ่งเหล่านั้นในการรักษาความผิดปกติ เหตุโรคภูมิต้านตนเองและเหตุอักเสบ